ERBB2 and gastric cancer: Although studies comparing FISH and SISH show concordance rates of 91–100%, and that both FISH and SISH are reliable for HER2 amplification testing [25], it is widely accepted that SISH is likely to become the most appropriate methodology for gastric cancer [8, 9].